Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Expert Insights

Anant Ramaswamy, MD, Tata Memorial Hospital
Videos
Addition of Docetaxel to FOLFOX/CAPOX Backbone Fails to Improve OS in Advanced GEJ/Gastric Cancer
01/20/2024

Featuring Anant Ramaswamy, MD

Featuring Anant Ramaswamy, MD
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses...
01/20/2024
Oncology
Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre
Videos
Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
01/20/2024

Featuring Jeanne Tie, MBChB, MD

Featuring Jeanne Tie, MBChB, MD ...
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB,...
01/20/2024
Oncology
Ethan Ludmir, MD, MD Anderson Cancer Center
Videos
Adding Metastasis-Directed Therapy for Oligometastatic Pancreas Cancer
01/19/2024

Featuring Ethan Ludmir, MD

Featuring Ethan Ludmir, MD
Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.
Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.
Ethan Ludmir, MD, discusses...
01/19/2024
Oncology
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center
Videos
Global Treatment of Gastric/GEJ Cancer with Durvalumab Plus FLOT
01/19/2024

Featuring Yelena Janjigian, MD

Featuring Yelena Janjigian, MD ...
Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.
Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.
Yelena Janjigian, MD, discussed...
01/19/2024
Oncology
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Strategies for Treating Patients With Multiply Relapsed Multiple Myeloma
01/19/2024

Featuring Joseph Mikhael, MD

Featuring Joseph Mikhael, MD
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
01/19/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Benefits of MRD Testing for the Treatment of Patients With Multiple Myeloma
01/19/2024

Featuring Joseph Mikhael, MD 

Featuring Joseph Mikhael, MD 
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.
At the 2023 Lymphoma, Leukemia &...
01/19/2024
Lymphoma, Leukemia & Myeloma Network
Gilles Salles, MD, PhD
Videos
Examining Factors to Consider in the Treatment of Patients With Indolent B-Cell Lymphomas
01/15/2024

Featuring Gilles Salles, MD, PhD

Featuring Gilles Salles, MD, PhD ...
Gilles Salles, MD, PhD, offers advice for fellow oncologists in the B-cell lymphoma space, highlighting the need for strategically chosen therapies to minimize the risk of transformations.
Gilles Salles, MD, PhD, offers advice for fellow oncologists in the B-cell lymphoma space, highlighting the need for strategically chosen therapies to minimize the risk of transformations.
Gilles Salles, MD, PhD, offers...
01/15/2024
Oncology
Lorenzo Falchi, MD
Conference Coverage
Subcutaneous Mosunetuzumab Demonstrates Encouraging Efficacy, Manageable Safety as Frontline Therapy for High-Tumor Burden Follicular Lymphoma
01/12/2024

Featuring Lorenzo Falchi, MD

Featuring Lorenzo Falchi, MD
At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.
At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.
At the 65th ASH Annual Meeting,...
01/12/2024
Oncology
Adrian Wiestner, MD
Conference Coverage
Exploring Possibilities for the Future of Chronic Lymphocytic Leukemia Treatment
01/12/2024

Featuring Adrian Wiestner, MD

Featuring Adrian Wiestner, MD
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.
At the 65th ASH Annual Meeting,...
01/12/2024
Oncology
Jeffrey Matous, MD, Sarah Cannon Research Institute
Conference Coverage
Talquetamab Plus Pomalidomide Shows Promising Efficacy, Manageable Safety for Patients With MM
01/11/2024

Featuring Jeffrey Matous, MD

Featuring Jeffrey Matous, MD
At the 65th ASH Annual Meeting, Jeffrey Matous, MD, shared initial trial results that talquetamab plus pomalidomide demonstrated rapid, deep responses among patients with R/R multiple myeloma and ≥2 prior lines of therapy.
At the 65th ASH Annual Meeting, Jeffrey Matous, MD, shared initial trial results that talquetamab plus pomalidomide demonstrated rapid, deep responses among patients with R/R multiple myeloma and ≥2 prior lines of therapy.
At the 65th ASH Annual Meeting,...
01/11/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement